Guest guest Posted July 10, 2007 Report Share Posted July 10, 2007 Hi all; an interesting note from the realm of convergence: BASEL, SWITZERLAND -- July 15, 2005 -- Treatment with the innovative cancer drug Tarceva® (erlotinib) in patients with advanced non-small cell lung cancer (NSCLC) resulted in significantly longer survival compared to placebo (42.5% improvement), according to a landmark study published in the New England Journal of Medicine (NEJM). Tarceva is an oral, once-daily therapy from a novel class of anti-cancer drugs known as 'EGFR inhibitors' (epidermal growth factor receptor inhibitors) and it is the first EGFR inhibitor to have demonstrated a survival benefit in cancer. Lung Governs the Skin, right? A small note on the technicalities: the term " epidermal " in this case is referring to the early bioassay. EGF is active on a wide variety of cell types, but /is/ especially active on epithelial (skin, or " surface " ) cells. Hugo _________ Mail is the world's favourite email. Don't settle for less, sign up for your free account today http://uk.rd./evt=44106/*http://uk.docs./mail/winter07.html Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.